A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMvigor 010
- Sponsors Chugai Pharmaceutical; Roche
- 13 Nov 2017 Planned End Date changed from 30 Apr 2022 to 10 May 2022.
- 13 Nov 2017 Planned primary completion date changed from 4 Oct 2019 to 10 Jan 2020.
- 10 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 4 Oct 2019.